Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 8/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13297521 | 1.00 | VDR (0.78) | VDR | |
| SCHEMBL13525336 | 1.00 | VDR (0.78) | VDR | |
| SCHEMBL10020259 | 1.00 | VDR (0.78) | VDR | |
| SCHEMBL14219118 | 0.90 | VDR (0.71) | VDR | |
| SCHEMBL12712528 | 0.89 | VDR (0.70) | VDR | |
| SCHEMBL12712505 | 0.88 | VDR (0.69) | VDR | |
| SCHEMBL9010457 | 0.88 | VDR (0.69) | VDR | |
| SCHEMBL14959189 | 0.86 | VDR (0.66) | VDR | |
| SCHEMBL14494378 | 0.85 | VDR (0.73) | VDR | |
| SCHEMBL14494340 | 0.85 | VDR (0.73) | VDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114859-B2 | anticarcinogenic agent; arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte; inhibiting adipocyte differentiation and stearoyl CoA desaturase (SCD-1) gene transcription; skin disorder, psoriasis, obesity, antiinflammatory agent | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-02-14 | — | — | US | disclosed |
| US-8114859-B2 | anticarcinogenic agent; arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte; inhibiting adipocyte differentiation and stearoyl CoA desaturase (SCD-1) gene transcription; skin disorder, psoriasis, obesity, antiinflammatory agent | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-02-14 | — | — | US | disclosed |
| US-20080081799-A1 | 2-Methylene-(20S,25S)-19,27-Dinor-(22E)-Vitamin D Analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2008-04-03 | — | — | US | disclosed |
| US-20080081799-A1 | 2-Methylene-(20S,25S)-19,27-Dinor-(22E)-Vitamin D Analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2008-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081799-A1 | 2-Methylene-(20S,25S)-19,27-Dinor-(22E)-Vitamin D Analogs | CYP24A1, CYP27B1, VDR | VDR 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.